BBG Advanced Therapies and CELLforCURE Form Transatlantic ATMP Manufacturing Partnership

BBG Advanced Therapies (BBGAT) announced a partnership with CELLforCURE this week to support the development and large-scale production of advanced therapy medicinal products (ATMPs).

CELLforCURE, part of SEQENS Group, is a European Medicines Agency (EMA)-authorized and FDA-compliant contract development and manufacturing organization that provides development and manufacturing services for advanced therapies.

BBGAT, a subsidiary of BioBridge Global, provides custom solutions to accelerate the development of cell and gene therapies. BBGAT also maintains the world’s only mobile leukapheresis center.

The partnership establishes a transatlantic network, enabling U.S. companies to access CELLforCURE’s European manufacturing capabilities while giving European developers the ability to leverage BBGAT’s U.S. production capacities. Together, the companies aim to accelerate therapy development, support multinational clinical trials and expand patient access to ATMPs worldwide.